Reflections on FDA Draft Guidance on Bayesian Methods in Trials—Protecting Scientific Integrity and Evidentiary Standards
This Perspective discusses the use of bayesian methods in clinical trials and the importance of having US Food and Drug Administration (FDA) guidance that provides substantive insights about the methods’ proper role.
Authors
- Lori E. Dodd (ORCID: https://orcid.org/0000-0002-3433-5429)
- Holly Janes (ORCID: https://orcid.org/0000-0002-3237-984X)
- Thomas R. Fleming
- Scott R. Evans
Institutions
- George Washington University (US)
- University of Washington (US)
- Fred Hutch Cancer Center (US)
- National Institute of Allergy and Infectious Diseases (US)
Publication Details
- Journal
- JAMA
- Published
- 2026-03-23
- DOI
- https://doi.org/10.1001/jama.2026.4175
- Primary Topic
- Statistical Methods in Clinical Trials
- Type
- article
- Field-Weighted Citation Impact
- 0.00